DK1079856T3 - Humanized antibodies for recognition of verotoxin II as well as cell line for production of same - Google Patents

Humanized antibodies for recognition of verotoxin II as well as cell line for production of same

Info

Publication number
DK1079856T3
DK1079856T3 DK99924395T DK99924395T DK1079856T3 DK 1079856 T3 DK1079856 T3 DK 1079856T3 DK 99924395 T DK99924395 T DK 99924395T DK 99924395 T DK99924395 T DK 99924395T DK 1079856 T3 DK1079856 T3 DK 1079856T3
Authority
DK
Denmark
Prior art keywords
verotoxin
humanized antibodies
recognition
production
well
Prior art date
Application number
DK99924395T
Other languages
Danish (da)
Inventor
Man Sung Co
Yoh-Ichi Matsumoto
Atsuchi Imaizumi
Tsuyoshi Kimura
Tae Takedo
Maximiliano Vasques
Original Assignee
Teijin Ltd
Pdl Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd, Pdl Biopharma Inc filed Critical Teijin Ltd
Application granted granted Critical
Publication of DK1079856T3 publication Critical patent/DK1079856T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides humanized antibodies that specifically bind to, and preferably, neutralize, verotoxin II (VT2). The antibodies are useful for treating patients suffering from, or at risk of suffering, toxic effects of verotoxin.
DK99924395T 1998-05-20 1999-05-19 Humanized antibodies for recognition of verotoxin II as well as cell line for production of same DK1079856T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8657098P 1998-05-20 1998-05-20

Publications (1)

Publication Number Publication Date
DK1079856T3 true DK1079856T3 (en) 2006-12-04

Family

ID=22199443

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99924395T DK1079856T3 (en) 1998-05-20 1999-05-19 Humanized antibodies for recognition of verotoxin II as well as cell line for production of same

Country Status (20)

Country Link
US (1) US7846435B1 (en)
EP (1) EP1079856B1 (en)
JP (1) JP4044733B2 (en)
KR (1) KR100548167B1 (en)
CN (1) CN1330375C (en)
AT (1) ATE335504T1 (en)
AU (1) AU748852B2 (en)
BR (1) BR9910589A (en)
CA (1) CA2328485C (en)
DE (1) DE69932719T2 (en)
DK (1) DK1079856T3 (en)
ES (1) ES2270598T3 (en)
HK (1) HK1036215A1 (en)
IL (2) IL139571A0 (en)
NO (1) NO326197B1 (en)
NZ (1) NZ508119A (en)
PT (1) PT1079856E (en)
RU (1) RU2217166C2 (en)
WO (1) WO1999059629A1 (en)
ZA (1) ZA200006370B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
AU2007240614B2 (en) 2006-04-20 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on Shiga toxin type 1 protein
CA2748873C (en) 2009-01-23 2017-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
JP6674603B2 (en) * 2013-05-27 2020-04-01 イムノヴァ エス．エー．Ｉｎｍｕｎｏｖａ Ｓ．Ａ． Chimera of Brucella lumazine synthase and B subunit of AB5 toxin
AU2015206002B2 (en) * 2014-01-16 2020-06-11 Mario Umberto Francesco MONDELLI Neutralizing human monoclonal antibodies against Hepatitis B Virus surface antigen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3236667B2 (en) 1991-06-28 2001-12-10 三菱化学株式会社 Human monoclonal antibody and gene encoding the same, hybridoma and antitumor agent
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
AU667533B2 (en) 1992-03-26 1996-03-28 Microcarb, Inc. Monospecific polyclonal antibodies to shiga-like toxins
CA2078716A1 (en) 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
US5747272A (en) 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
CA2116179C (en) 1994-02-22 2008-01-08 C. A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
EP0817647A4 (en) 1995-03-24 2002-10-30 Promega Corp Treatment for verotoxin-producing escherichia coli
CA2163716C (en) 1995-11-24 2009-05-19 Clifford A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
DE19641466A1 (en) 1996-10-09 1998-04-16 Biotest Pharma Gmbh Oral use of an immunoglobulin preparation for the prevention of hemolytic uremic syndrome and a preparation therefor
WO1998020903A1 (en) * 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease

Also Published As

Publication number Publication date
JP4044733B2 (en) 2008-02-06
WO1999059629A1 (en) 1999-11-25
CN1330375C (en) 2007-08-08
JP2002515230A (en) 2002-05-28
IL139571A0 (en) 2002-02-10
NZ508119A (en) 2003-06-30
US7846435B1 (en) 2010-12-07
DE69932719T2 (en) 2007-09-13
AU4090499A (en) 1999-12-06
CN1301175A (en) 2001-06-27
KR100548167B1 (en) 2006-01-31
CA2328485C (en) 2011-05-03
NO20005833D0 (en) 2000-11-17
DE69932719D1 (en) 2006-09-21
EP1079856B1 (en) 2006-08-09
EP1079856A4 (en) 2002-03-13
EP1079856A1 (en) 2001-03-07
KR20010052367A (en) 2001-06-25
ZA200006370B (en) 2001-08-22
RU2217166C2 (en) 2003-11-27
HK1036215A1 (en) 2001-12-28
ES2270598T3 (en) 2007-04-01
BR9910589A (en) 2001-01-16
NO20005833L (en) 2001-01-15
NO326197B1 (en) 2008-10-13
PT1079856E (en) 2006-12-29
ATE335504T1 (en) 2006-09-15
CA2328485A1 (en) 1999-11-25
AU748852B2 (en) 2002-06-13
IL139571A (en) 2009-09-22

Similar Documents

Publication Publication Date Title
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
TR200103756T2 (en) Treatment with humanized anti-ErbB2 antibodies and anti-ErbB2 antibodies.
RS80704A (en) ANTI- av?6.ANTIBODIES
DE50106127D1 (en) USE OF TRIFUNCTIONAL BISPEQIFIC AND TRISPECTIVE ANTIBODIES FOR THE TREATMENT OF MALIGNEM ASZITES
EP2363404A3 (en) PSMA antibodies
ATE477273T1 (en) HUMANIZED ANTIBODIES AGAINST GAMMA INTERFERON
TR200200472T2 (en) Dosages for treatment with anti-Erb B2 antibodies
DK1951759T3 (en) Anti-EGFR antibodies
EA201070695A1 (en) MOLECULES OF HUMANIZED ANTIBODIES SPECIFIC TO IL-31
MX2008007502A (en) Anti-mn antibodies and methods of using same.
DE60135029D1 (en) USE OF SOLUBLE CTLA4 MUTANTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
ATE373719T1 (en) HUMANIZED ANTIBODIES AGAINST CCR2 AND METHOD OF USE THEREOF
BRPI0506679A (en) Methods of Treating Osteoarthritis with IL-6 Antagonists
RS53984B1 (en) Ip-10 antibodies and their uses
DE69638269D1 (en) HIGH-AFFINE HUMAN ANTIBODY AGAINST TUMORANTIGENE
MXPA05005925A (en) Antibodies directed to phospholipase a2 and uses thereof.
EA200500232A1 (en) METHODS OF DIAGNOSTICS AND TREATMENT OF PREECLAMPSIA OR ECLAMPSIA
PT1572087E (en) Antibodies against cancer antigen tmeff2 and uses thereof
AU2002951409A0 (en) Methods for regulating cancer
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
DK1079856T3 (en) Humanized antibodies for recognition of verotoxin II as well as cell line for production of same
WO2004053102A3 (en) Antibodies to treat cancer
WO2003072727A3 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
ATE296316T1 (en) MONOCLONAL ANTIBODIES DIRECTED AGAINST HUMAN MCM3 PROTEIN, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE